Targeted contrast agents to better detect pancreatic tunor and its zinc content by MRI on mice

Project description

Determining zinc content in cancer with MRI

Prompt diagnosis and therapies for pancreatic cancer are limited, leading to a dismal prognosis and low survival rate. Emerging evidence indicates that pancreatic cancer cells present low levels of zinc importers and zinc content, while treatment with the zinc ionophore clioquinol inhibits tumour growth. The EU-funded tZR-CA-InVivo project aims to develop a magnetic resonance imaging tool, namely a zinc-responsive contrast agent to quantify zinc content in tissues. The contrasting agent will be designed to specifically target the tumour and provide a means for monitoring zinc levels in patients with cancer and evaluate the need to increase it.

Fields of science

• medical and health sciences › clinical medicine › oncology › prostate cancer
• social sciences › political sciences
• transition metals
• diagnostic imaging › magnetic resonance imaging
• medical and health sciences › clinical medicine › oncology › pancreatic cancer

Programme(s)

• H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme
• H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility

Topic(s)

• MSCA-IF-2019 - Individual Fellowships

Call for proposal

H2020-MSCA-IF-2019

See other projects for this call

Funding Scheme

MSCA-IF-EF-RI - RI – Reintegration panel

Coordinator

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS

Net EU contribution

€ 196 707,84

Address

Rue Michel Ange 3
75794 Paris
France

Activity type

Research Organisations

Non-EU contribution

€ 0,00

Region

Ile-de-France › Ile-de-France › Paris